This past fall, the National Institutes of Health, the Food and Drug Administration and other partners launched the Bespoke Gene Therapy Consortium in an effort to leverage adeno-associated viruses as vectors to treat rare diseases. The initiative seeks to streamline research to clinical use, driving efficiencies into the traditional research and development process. FDA leader Peter Marks and NIH’s P.J. Brooks discuss the consortium’s work and how it aims to help people with rare diseases.
HealthCast
Season 2
Episode 39
21m listen
Gene Therapy is Fighting Rare Diseases in FDA, NIH Program
Share
The technique aims to treat some diseases by gene replacement.
-
Dr. Peter Marks Director CBER, FDA -
Deputy Director, Office of Rare Diseases Research NCATS, NIH
Related Content
-
HHS Looks to Centralize IT Buying, Speed Access to Emerging Tech
HHS is centralizing IT procurement while pursuing faster acquisition tools for AI and other emerging technologies.
9m watch -
VA Employees Save 6 Hours a Week With AI Tools
VA AI chief Kimberly McManus said AI tools are helping improve veteran care, reduce opioid overdose mortality and save time for employees.
4m watch -
FEHRM CTO: TEFCA Could Take Federal Health Data Exchange to ‘Next Evolution’
FEHRM CTO Lance Scott discusses efforts to modernize and improve interoperability of electronic health records across the federal government.
7m watch -
Inside ASPR’s Efforts to Bolster Healthcare Sector Cyber Resilience
HHS ASPR’s Bob Bastani details how governance, standards and migration planning can help against emerging threats to medical data and devices.
12m watch